While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Questioned by senators at a Thursday hearing, President Trump's FDA nominee said he would reevaluate which scientific topics ...

The Johns Hopkins surgeon highlighted rapid growth at the agency, but pledged key staff will have “all the resources they ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leadership transition at the unorthodox drug ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.